Man Group PLC Rigel Pharmaceuticals Inc Transaction History

Man Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.12 - $1.57 $135,522 - $189,973	121,002 New	121,002 $179,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $16,500 - $26,400	13,200 Added 10.15%	143,312 $189,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $70,119 - $1.25 Million	104,656 Added 411.13%	130,112 $195,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $28,001 - $310,563	25,456 New	25,456 $30,000
Q4 2019 Feb 18, 2020	SELL	$1.6 - $2.43 $17,600 - $26,730	-11,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.63 - $2.62 $17,930 - $28,820	11,000 New	11,000 $21,000
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $114,400 - $157,960	-44,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $124,520 - $180,840	44,000 New	44,000 $125,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.